Fluxome A/S, Danish based parent to Fluxome Inc., recently filed for formal reconstruction. This action was taken in part to preserve assets for its U.S. commercial operations for the production and selling of resveratrol. At this time, the Danish facility has closed its research activities during this reconstruction phase.
Fluxome A/S, while in reconstruction, is in the process of obtaining additional funding to continue its operations both here and abroad and/or a sale of its assets. In the meantime, it is business as usual for the resveratrol operation and customers should not notice any disruption in supply.